Cervical cancer: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MYC 0
• MAPK 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Cervical Cancers Escaping HPV Screening: Decoding HPV-Independent Carcinogenesis through Multi-Omics Profiling (ESCAPE-HPV)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,493,450· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  Offering combined HPV vaccination and HPV test-based cervical screening to vulnerable populations. A hybrid efficacy and implementation study. (HPV-FASTER-Implement)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €6,602,445· until Dec 2029· 8 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Understanding vaccination hesitancy and evaluating single dose and gender-neutral vaccination for improving uptake of HPV vaccines in West and East Africa. (IMPROVE-HPV)

  Institut Catala D'oncologia· Hospitalet de Llobregat, Spain· EU contribution €3,613,288· until May 2028· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Engineering B cells to fight cancer (EngineerBcells)

  Tel Aviv University· Tel Aviv, Israel· EU contribution €1,996,250· until Sept 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Dual screening by Spectral Artificial Visual Examination (SAVE) for Female Genital Schistosomiasis (FGS) and cervical cancer. Digital, new, low-cost, and simple screening and training. (DUALSAVE-FGS)

  Oslo Universitetssykehus Hf· Oslo, Norway· EU contribution €7,984,441· until Aug 2027· 6 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Disease and vaccine monitoring based on non-invasive genital tract liquid biopsy sampling. (URISAMP)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €1,499,265· until Apr 2028

  The disease is named only in the funder's project summary, not in the title.

6 of 6 running projects, newest first. Listed amounts together: €23.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

  NCT01226316· AstraZeneca· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 21
• Gene Expression Profiling 70
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 18
• Metabolomics 9
• Mass Spectrometry 4
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 66
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 63
• Deep Learning 50
• Cohort Studies 82
• Genome-Wide Association Study 14

• Single-cell sequencing reveals immune networks and metabolic reprogramming in gynecological malignancies.

  Front Immunol, Oct 2026

• Functional single-cell omics in gynecological cancers immunotherapy: from heterogeneity dissection to clinical translation.

  Front Immunol, Oct 2026

• Integrating scRNA-Seq and Spatial Transcriptomics Reveal Novel Risk Stratification Signatures in Cervical Carcinoma.

  J Med Virol, Oct 2026

• Diagnostic performance of artificial intelligence models trained on scattered single-cell images is not preserved for hyperchromatic crowded cell groups in cervical cytology.

  Cancer Cytopathol, Sept 2026

• Spatially organized macrophage-T-cell crosstalk in cervical cancer: insights from single-cell and spatial omics.

  Front Immunol, Jul 2026

• Phosphoinositide metabolism-related prognostic genes and their prognostic value in cervical cancer: an investigation based on transcriptome, single-cell analyses and verification.

  BMC Cancer, Jul 2026

• Immune heterogeneity and therapeutic resistance in gynecological malignancies.

  Front Immunol, Jun 2026

• Single-Cell Selective Retrieval Method Using Cone-Shaped Light-Responsive Gas-Generating Polymer Microscaffold Array Chip.

  Sensors (Basel), Apr 2026

• Tumor Core-Edge Divergence in T-Cell Exhaustion and Clonal Expansion in HPV-Related Cervical Squamous Cell Carcinoma Unveiled by Simultaneous Single-Cell RNA and TCR Sequencing.

  J Med Virol, Apr 2026

• Research advances in Raman imaging of single-cell phenotypes in fatty acid metabolism in cancers.

  Spectrochim Acta A Mol Biomol Spectrosc, Feb 2026

See which targets of this disease your abstract mentions, and go to the people working on them.